FDA Opens Call for Comments on Redefining ‘Dietary Substance’ in DSHEA

Why It Matters

Clarifying the “dietary substance” definition could remove a long‑standing regulatory bottleneck, allowing innovators to bring scientifically advanced ingredients to market faster. For consumers, the change promises greater access to novel nutrients while also raising questions about transparency and safety oversight. The outcome will influence investment flows into precision‑fermentation startups and could set a precedent for how emerging food‑tech products are regulated in the United States. Beyond the supplement aisle, a broader definition may ripple into related categories such as functional foods and nutraceuticals, prompting a reevaluation of where the line between food and supplement truly lies. Policymakers, industry leaders and consumer groups will all be watching the FDA’s next move to gauge the balance between fostering innovation and protecting public health.

Key Takeaways

• FDA seeks stakeholder comments by April 27 on redefining “dietary substance” under DSHEA.
• AHPA argues the current interpretation blocks novel ingredients not found in conventional foods.
• CRN urges modernization to reduce reliance on GRAS pathways for supplement innovators.
• Potential inclusion of proteins, peptides, enzymes and microbials could add $5 billion to U.S. supplement sales.
• Upcoming FDA guidance in its 2026 priority deliverables will shape safety and labeling standards.

Pulse Analysis

The FDA’s invitation to revisit the “dietary substance” clause reflects a broader regulatory shift toward accommodating biotech‑derived ingredients. Historically, the agency has applied a conservative lens, treating anything not traditionally consumed as a food as outside the supplement realm. That stance has forced companies to file GRAS petitions or pursue food‑additive approvals—processes that are costly and time‑consuming. By explicitly recognizing precision‑fermented proteins and microbially produced enzymes as legitimate dietary substances, the FDA could streamline the pathway, lowering barriers to entry for startups and accelerating product pipelines.

However, the move is not without risk. Expanding the definition without parallel enhancements to safety assessment could create a regulatory vacuum, where novel compounds enter the market with limited post‑market surveillance. Consumer‑trust hinges on transparent labeling that distinguishes naturally sourced ingredients from those engineered in a lab. The AHPA’s emphasis on “facts‑forward” labeling suggests that any rule change will likely be accompanied by stricter disclosure requirements, a compromise that could satisfy both innovators and consumer‑advocacy groups.

In the competitive landscape, early adopters that align product development with the forthcoming guidance will gain a first‑mover advantage. Large supplement firms with in‑house biotech capabilities are poised to integrate precision‑fermented ingredients into existing brands, while smaller players may partner with specialized fermentation companies to co‑develop niche formulations. The next few months will reveal whether the FDA’s clarification becomes a catalyst for a new wave of science‑driven supplements or a cautionary tale of regulatory overreach.